Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 7, 2016

Mast Therapeutics begins enrolment for Phase II INABLE-TRAINING study of AIR001 to treat HFpEF

US-based biopharmaceutical company Mast Therapeutics has begun enrolment for its Phase II INABLE-TRAINING study of AIR001 to treat heart failure with preserved ejection fraction (HFpEF).

US-based biopharmaceutical company Mast Therapeutics has begun enrolment for its Phase II INABLE-TRAINING study of AIR001 to treat heart failure with preserved ejection fraction (HFpEF).

AIR001 is a sodium nitrite solution developed for intermittent inhalation via nebulisation. Nitrite is a direct vasodilator and can be recycled into in vivo to form nitric oxide (NO) that is independent of the classical NO synthase (NOS) pathway.

The NO formation results in several clinically beneficial effects such as the dilation of blood vessels and reduction of inflammation and undesirable cell growth.

Formation of NO from sodium nitrite is not dependent upon endothelial function and is expressed in the setting of tissue hypoxia and acidosis, conditions in which NOS activity is evident.

The Phase II randomised, double-blind, parallel-group and placebo-controlled Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training (INABLE-TRAINING) trial is being conducted to test the effect of inhaled AIR001 on chronic exercise training (ET) in subjects with HFpEF than placebo.

"There are now three Phase II studies actively enrolling patients to evaluate AIR001 for the treatment of HFpEF and we remain excited about its potential in this indication."

Mast Therapeutics CEO Brian Culley said: "There are now three Phase II studies actively enrolling patients to evaluate AIR001 for the treatment of HFpEF and we remain excited about its potential in this indication.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

"Data from this and other studies will help guide our clinical and regulatory strategy in this area of significant unmet need.

"Currently, HFpEF affects approximately half of the more than five million people in the US diagnosed with heart failure and has no proven effective treatment."

The study is expected to enrol about 68 patients who will undergo 12 weeks of cardiac rehabilitation, including exercise training, and will receive either AIR001 or placebo inhalation solution during the training period.

It is firstly focused on determining the efficacy of inhaled AIR001 in addition to ET in improving exercise capacity and hemodynamic reserve in HFpEF.

Secondly, it will evaluate the ability of AIR001 in addition to ET in improving daily activity levels and quality of life (QOL) while reducing symptoms of effort intolerance during ET.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU